There are several classes of drugs that are used to treat Pulmonary Arterial Hypertension. These include endothelin receptor antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5 inhibitors), prostacyclin analogues, and soluble guanylate cyclase stimulators (SGCs).
Endothelin receptor antagonists (ERAs) block the action of a hormone called endothelin, which is involved in the constriction of blood vessels. By blocking the action of endothelin, ERAs help to dilate the blood vessels in the lungs, reducing resistance to blood flow. ERAs also have anti-inflammatory and anti-proliferative effects, which may help to slow the progression of Pulmonary Arterial Hypertension Drug. There are currently three ERAs approved for the treatment of PAH: bosentan, ambrisentan, and macitentan.
Phosphodiesterase type 5 inhibitors (PDE5 inhibitors) increase the production of a molecule called cyclic guanosine monophosphate (cGMP), which helps to relax the smooth muscle cells in the blood vessels. This relaxation leads to vasodilation and improved blood flow. PDE5 inhibitors also have anti-proliferative effects, which may help to slow the progression of Pulmonary Arterial Hypertension Drug. There are currently three PDE5 inhibitors approved for the treatment of PAH: sildenafil, tadalafil, and vardenafil.
Read More- https://cmiblogdailydose.blogspot.com/2023/03/pulmonary-arterial-hypertension-drug.html
